Methods of treating human papillomavirus
Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.
1. A method of treating human papillomavirus (HPV), comprising the step of directly applying a therapeutically effective amount of ranpirnase to an HPV-infected region of a living subject in need of such treatment.
2. A method of treating human papillomavirus, comprising the step of directly applying a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO.: 1 to an HPV-infected region of a living subject in need of such treatment.
3. A method of treating type 11 human papillomavirus (HPV), comprising the step of directly applying a therapeutically effective amount of ranpirnase to an HPV-infected region of a living subject in need of such treatment.
4. A method of treating type 11 human papillomavirus, comprising the step of directly applying a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO.: 1 to an HPV-infected region of a living subject in need of such treatment.
5. A method of treating human papillomavirus (HPV), comprising the step of directly applying a therapeutically effective amount of:
a. ranpirnase, or
b. a polypeptide having the amino acid sequence of SEQ ID NO.: 1 to an HPV-infected region of a living subject in need of such treatment.